Drug Profile
Interleukin-2 gene therapy (VCL-IM01)
Alternative Names: Electroporation-delivered DNA immunotherapy against metastatic melanoma - Inovio/Fresh Tracks Therapeutics; IL-2 plasmid DNA/lipid complex (Leuvectin); IL-2-based DNA vaccine - Fresh Tracks Therapeutics; IL-2/EP - Fresh Tracks Therapeutics; Interleukin-2 gene therapy - Fresh Tracks Therapeutics; VCL-1M01; VCL-IM01Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics; Inovio Pharmaceuticals
- Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
- Mechanism of Action Gene transference; Immunostimulants; Interleukin 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Prostate cancer; Renal cancer
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 18 Dec 2008 Final efficacy and adverse events data from a phase I trial in Metastatic melanoma presented at the DNA Vaccines 2008 Conference (DNA Vaccines-2008)